newsfilter
← Latest News
Business Wire·

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the